

## EQA round: CC2/23 - Cystatin C

Deadline: 25.8.2023

Setup: groups - manufacturer of kit; Slovakia; minimal size of the groups n = 5

RoM = robust average

SD = standard deviation

CV = coefficient of variation

N<sub>tot</sub> = total number of the resultsN<sub>out</sub> = number of the results removed before calculation

AV = assigned value

U<sub>AV</sub> = expanded uncertainty of the assigned value (k = 2)D<sub>max</sub> = acceptable difference

LL = lower limit

UL = upper limit

N<sub>eva</sub> = number of the results assessedN<sub>suc</sub> = number of successful resultsS<sub>rel</sub> = relative success

Test Sample Group	[unit]	RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	Comparability					N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub> [%]
							AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL			
(106) Cystatin C	[mg/L]				10							10	10	100
Sample A												10	10	100
Other					10	0						10		
							1x 3, 2x 46, 1x 58, 3x 60, 1x 91, 1x 162, 1x 179							
Sample B												10	10	100
Other					10	0						10		
							1x 3, 2x 46, 1x 58, 3x 60, 1x 91, 1x 162, 1x 179							